Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
A phase 3 trial of Patidegib Topical Gel in basal cell carcinoma, run by Sol-Gel Technologies, Ltd., active and no longer recruiting.
Overview
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome is a phase 3 interventional study registered as NCT06050122 by Sol-Gel Technologies, Ltd., with 140 participants enrolled, started 2024-03-17 and due to reach its primary completion in 2026-10. Interventions recorded: Patidegib Topical Gel and Patidegib Topical Gel with no active patidegib.
Similar pages
not linked directly; found by shared links- TrialClinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Shares Basal cell carcinoma and the tag pipeline.
- TrialPlacebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Shares Basal cell carcinoma and the tag pipeline.
- TrialL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Shares Basal cell carcinoma and the tag pipeline.
- TrialL19IL2/TNF in Patients With Basal Cell Carcinoma
Shares Basal cell carcinoma and the tag pipeline.
- TrialStudy to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Shares Basal cell carcinoma and the tag pipeline.